Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207651 | 0.89 | PTGER1 (0.49) | MAPK14PTGER1 | |
| SCHEMBL5203927 | 0.86 | MAPK14 (0.49) | MAPK14PTGER1MAOB | |
| SCHEMBL5202766 | 0.86 | MAPK14 (0.49) | MAPK14PTGER1MAOB | |
| SCHEMBL5204564 | 0.85 | MAPK14 (0.44) | MAPK14PTGER1MAOB | |
| SCHEMBL5205590 | 0.81 | MAOB (0.39) | CYP1A1CYP1A2CYP1B1MAPK14PTGER1 | |
| SCHEMBL5202236 | 0.81 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL5207032 | 0.81 | MAPK14 (0.47) | CYP1A1CYP1A2CYP1B1MAPK14 | |
| SCHEMBL5202380 | 0.74 | MAOB (0.42) | MAPK14PTGER1MAOB | |
| SCHEMBL3527353 | 0.73 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL5237979 | 0.73 | MAPK14 (0.49) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802590-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | Pharmacia & Upjohn Company LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | disclosed |